Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × trametinib × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Melanoma 1

Interventions

Carboplatin 33 Cisplatin 28 pembrolizumab 27 Paclitaxel 26 Pemetrexed 20 Gemcitabine 19 Nivolumab 18 Rituximab 15 Dexamethasone 15 Ipilimumab 12 Fluorouracil 11 Docetaxel 11 Cyclophosphamide 11 durvalumab 10 Lenalidomide 9 Capecitabine 9 Bevacizumab 9 olaparib 8 atezolizumab 8 Doxorubicin 8 Cytarabine 8 130-nm albumin-bound paclitaxel 8 daratumumab 7 Prednisone 7 Leucovorin 7 Etoposide 7 Bortezomib 7 venetoclax 6 osimertinib 6 Trastuzumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682083 2023-08-30

COMBI-AD

Novartis

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡